Skip navigation


Current DateTime: 09:45:23 10 Nov 2009
LinksList Documentid: 24355697

FEATURED QUIZZES


Current DateTime: 09:45:23 10 Nov 2009
LinksList Documentid: 33793611

Current DateTime: 09:45:23 10 Nov 2009
LinksList Documentid: 24890560
  • Winterizing Your Portfolio

      If 2009 was the winter of our discontent, will 2010 be a winter wonderland for investors? A lot depends on the recovery—or lack thereof.

  • Investor's Guide to Real Estate

      Some even say the long-awaited recovery is here. Regardless, buyers and sellers alike can profit from our guide.

  • Alternative Investing

      Stocks and bonds? Sure. But it's a big world out there for investors.

powered by digg
Invitrogen to Buy Applied Biosystems for $6.7 Billion
By: Reuters | 12 Jun 2008 | 09:37 AM ET
Text Size

Invitrogen plans to buy Applied Biosystems in a deal valued at $6.7 billion to form a massive provider of research tools for the life sciences industry, the companies said on Thursday.

The purchase price of $38 per share in cash and stock represents a premium of 17 percent over Applied Biosystems' closing price on Wednesday and 12 percent over its average closing price over the past 30 days. The split is expected to be 45 percent cash and 55 percent Invitrogen stock.

The combined company will generate about $3.5 billion in combined sales, offering a wide variety of products in areas such as genetic analysis, proteomics, cell biology and cell systems.

Applied Biosystems' equipment includes mass spectrometers, which can measure the molecular weight of proteins and thereby identify them.

Invitrogen [IVGN  Loading...      ()   ] shares fell 10 percent after the deal announcement, while Applied Biosystems [ABI  Loading...      ()   ] rose 8 percent.

"In the most general terms, it makes sense in terms of their expertise in molecular biology, efficiencies in combined sales forces, overlap on product line and intellectual property interests," said Deutsche Bank analyst Ross Muken. Such a combination was a source of speculation at a conference in Denver last week, he added.

Upon closing, Invitrogen shareholders would own the majority of the merged company, which would be named Applied Biosystems.

Applied Biosystems is one of two tracking stocks of Applera, which announced the deal with Invitrogen. Celera Group [CRA  Loading...      ()   ] is the other.

The companies expect the merger to close in the fall and to be neutral to or slightly help earnings per share in the first year and significantly positive in the second year.

Invitrogen shares fell $4.35 to $39 in early electronic trading from a Wednesday close of $43.35 on Nasdaq.

Applied Biosystems shares rose to $35 from Wednesday's New York Stock Exchange close of $32.44.

Copyright 2009 Reuters. Click for restrictions.
Tools:
Print EmailAdd This share icon
  • digg share

CNBC HIGHLIGHTS

  • From politicians to CEOs to companies, here's your chance to vote for the winners and losers of 2009.
  • What’s powering your microwave, fridge and computer? Part of it is fuel from Russian nuclear weapons. The NYT reports.
  • With prices well below peak, gems could add some sparkle to your investments.
  • Do free market libertarians really believe what they say about ethics and shareholder value? The Big Money takes a look.
  • On the anniversary of the fall of the Berlin Wall, many in the former Eastern Bloc recall communism fondly.
  • The opening of a virtual pet store in “World of Warcraft” could prove a cash bonanza for Activision-Blizzard.
ADD COMMENTS
Remaining characters


Current DateTime: 06:23:05 10 Nov 2009
LinksList Documentid: 29778428

Current DateTime: 01:02:20 10 Nov 2009
LinksList Documentid: 29779196

Current DateTime: 06:22:21 10 Nov 2009
LinksList Documentid: 29779199

Current DateTime: 01:06:21 10 Nov 2009
LinksList Documentid: 29779198
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
A Division of NBC Universal
Thomson ReutersThomson Reuters